Implantable defibrillators and β-blockers in patients with left ventricular dysfunction: Economic, ethical, and legal considerations

This article is going to be somewhat different than the typical article you might read on the treatment of heart failure. My goal is to get you to think in a different way about the use of primary prevention implantable cardioverter defibrillators and β-blockers in patients with left ventricular dys...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2007-04, Vol.153 (4), p.59-64
Main Author: Silver, Marc T., MD
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - economics
Adrenergic beta-Antagonists - therapeutic use
Cardiovascular
Clinical Trials as Topic
Costs and Cost Analysis
Defibrillators, Implantable - economics
Defibrillators, Implantable - ethics
Heart Failure - economics
Heart Failure - therapy
Humans
Malpractice
Ventricular Dysfunction, Left - economics
Ventricular Dysfunction, Left - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article is going to be somewhat different than the typical article you might read on the treatment of heart failure. My goal is to get you to think in a different way about the use of primary prevention implantable cardioverter defibrillators and β-blockers in patients with left ventricular dysfunction. Specifically, using the results from 3 landmark clinical trials—MADIT II, SCD-HeFT, and COMET—I am going to discuss the economic, ethical, and legal principles that underpin the use of these 2 therapies in patients with heart failure.
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2007.01.021